Silexion Therapeutics Ltd. (SLXNW) Stock Analysis & Investment Frameworks
Silexion Therapeutics Ltd. (SLXNW) stock analysis on Invetso. Review Silexion Therapeutics Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Silexion Therapeutics Ltd. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
Silexion Therapeutics Ltd. Key Financial Metrics
- Market Cap: $3366.00
- Revenue: $N/A
- ROE: -563.11%
- ROIC: 628.40%
- Dividend Yield: N/A
About Silexion Therapeutics Ltd.
Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer. Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.